Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lumakras
Pharma
BMS and Mirati's KRAS inhibitor Krazati moves beyond NSLC
Despite coming to market second, BMS' Mirati Therapeutics-inherited med Krazati has gained the lead on its Amgen rival Lumakras in a heated KRAS race.
Fraiser Kansteiner
Jun 24, 2024 8:53am
ASCO: BMS' confirmatory KRAS data leave FDA prospects unclear
Jun 1, 2024 8:00am
Amgen CEO nabs pay raise thanks to Horizon deal
Apr 18, 2024 5:08pm
BMS touts KRAS confirmatory trial win after Amgen's stumble
Mar 29, 2024 10:35am
Amgen's request for full approval of Lumakras denied by FDA
Dec 27, 2023 8:00am
Amgen sticks by Lumakras dose as ESMO data boost confidence
Oct 22, 2023 10:30am